We at Novus Biologicals are one of the leading antibody suppliers for diabetes research. An aging population, and the increasing incidence of type 2 diabetes, makes it an area of increasing interest - especially as there is often a close link to cancer. Metabolic studies and diabetes research go hand-in-hand. The glyoxylase system is part of this, removing metabolic by-products that would otherwise be toxic to the cell, and as such features highly on our antibody database.
The glyoxylase enzymes are responsible for deactivating reactive oxoaldehydes, such as MGO (methylglyoxal). MGO is a normal by-product of metabolism, and is formed in several ways e.g. by spontaneous formation from dihydroxyacetone phosphate, and by enzyme action on triosephosphate isomerase. At low concentrations MGO is cytostatic (i.e. a suppressor of cellular growth and reproduction). However, at millimolar concentrations it becomes highly cytotoxic. It is known to be a carcinogen and mutogen, and is damaging to intracellular components such as proteins and nucleic acids.
GLO1 is the first enzyme in the glyoxylase system, and critical to MGO detoxification. A member of the metalloglutathione (GSH) transferase superfamily, it catalyses the conversion of MGO (in the form of diastereomeric GSH- hemithioacetal adducts) to non-toxic S-lactoyl-glutathione, via a 1, 2 hydrogen transfer involving the reduction of glutathione. It is then further calalysed and recycled into the metabolic system.
-Western%20Blot-NBP1-19015-img0003.jpg "Western Blot: GLO1 Antibody")
Western Blot: GLO1 Antibody
GLO1 is widely studied in diabetes research. It is thought that inactivation of GLO1 is a cause of vascular complications in patients with diabetes. GLO1 antibodies are also used in oncology, as GLO1 has been shown to be upregulated in certain cancer cells.
Novus Biologicals offers many GLO1 reagents for your research needs including:
